###### Key messages

What is already known about this subject?
=========================================

-   Abatacept in combination with methotrexate induces remission more often than methotrexate alone after 12 months of treatment, with a greater proportion of patients with rheumatoid arthritis (RA) maintaining remission over 6 months following treatment withdrawal.

What does this study add?
=========================

-   These final results of the Assessing Very Early Rheumatoid arthritis Treatment (AVERT) study demonstrate that, after receiving only 12 months of disease-modifying antirheumatic drug therapy before withdrawal of all RA treatments, the majority of patients will experience a flare within 6 months of treatment withdrawal and very few will sustain major responses for 1 year.

-   The study provides the most complete data on re-treatment with abatacept plus methotrexate showing that this combination can restore remission or low disease activity in many patients who experienced a flare after treatment withdrawal, with good tolerability.

How might this impact on clinical practice?
===========================================

-   This is the first study to examine the effects of complete and rapid removal of all RA therapy, creating data that will inform future efforts to develop off-drug remission strategies.

Introduction {#s1}
============

In early rheumatoid arthritis (RA), a window may exist during which intensive treatment can alter the disease course, leading to improved long-term outcomes.[@R1] For patients achieving remission within this window, tapering or withdrawal of treatment may offer certain advantages if remission is sustained.[@R3] In order to develop biologic-free or even drug-free remission strategies,[@R3] we must better understand the ability of current therapies to sustain long-term off-drug remission, including the management of disease flares.

In the Assessing *﻿*Very Early Rheumatoid arthritis Treatment (AVERT) study, treatment-naïve patients with early RA were randomised to either subcutaneous abatacept plus methotrexate, subcutaneous abatacept or methotrexate monotherapy for 1 year followed by complete withdrawal of all RA-specific therapeutic agents, including corticosteroids, and then monitored for flares before re-treating with abatacept plus methotrexate. As previously reported, it demonstrated the benefits, including MRI improvements, of abatacept plus methotrexate versus methotrexate alone in inducing remission at 12 months and maintaining remission over the first 6 months after withdrawal of all RA treatment.[@R6] This report completes the description of the efficacy and safety outcomes over the full 12-month treatment withdrawal period and the benefits of 6 months of re-treatment after an RA flare. It also explores which clinical characteristics were associated with flare or with regaining disease control after re-treatment.

Methods {#s2}
=======

Study design and patient population {#s2-1}
-----------------------------------

Methodology of the phase IIIb AVERT study (NCT01142726) was published previously ([figure 1](#F1){ref-type="fig"}).[@R6] In the initial 12-month, double-blind treatment period, patients were randomised (1:1:1) to subcutaneous abatacept plus oral methotrexate, abatacept monotherapy plus oral placebo, or methotrexate monotherapy plus subcutaneous placebo. After 12 months, patients with Disease Activity Score (DAS)28 C reactive protein (CRP) \<3.2 could enter a 12-month withdrawal period and all RA treatments were stopped---abatacept immediately, and methotrexate and corticosteroids tapered over 1 month. Patients with protocol-defined RA flare after month 15 could receive open-label subcutaneous abatacept plus methotrexate in a 6-month re-treatment period. RA flare was defined as ≥2 of the following after the first 3 months of the withdrawal period: doubling of tender and swollen joint counts, increase in DAS28-CRP ≥1.2 (both from month 12) or investigator's judgement of RA flare. Abatacept was administered at 125 mg/week and methotrexate titrated to 10--20 mg/week.

![Study design. \*Randomisation stratified by corticosteroid use at baseline. DAS28-CRP, Disease Activity Score 28-C reactive protein; D/C, discontinuation; MTX, methotrexate; RA, rheumatoid arthritis. Reprinted from Emery P, et al. *Ann Rheum Dis* 2015;74:19-26, which is published under Creative Commons license CC BY-NC 4.0 (<https://creativecommons.org/licenses/by-nc/4.0/legalcode>).](rmdopen-2018-000840f01){#F1}

Eligibility criteria included age ≥18 years, active clinical synovitis of ≥2 joints for ≥8 weeks, persistent RA symptoms for ≤2 years, DAS28-CRP ≥3.2, anticyclic citrullinated peptide 2 (anti-CCP2) antibody positivity and methotrexate naïve/minimum exposure. Patients receiving oral corticosteroids had to be on a stable dose (≤10 mg/day) at baseline and maintain that dose until month 12; randomisation was stratiﬁed by baseline corticosteroid use (yes/no).

Assessments and statistical analyses {#s2-2}
------------------------------------

Proportions of patients in the withdrawal period with remission, defined as DAS28-CRP \<2.6, Clinical Disease Activity Index (CDAI) ≤2.8, Simplified Disease Activity Index (SDAI) ≤3.3 and Boolean criteria,[@R8] and with low disease activity (LDA) defined as DAS28-CRP \<3.2, were described over time. For patients entering withdrawal, time to first RA flare during withdrawal and predictors of time to flare were analysed using a Cox proportional-hazards model including the following parameters at initial study entry: randomised treatment, DAS28-CRP, swollen joint count, Patient Global Assessment of Disease Activity (PtGA), corticosteroid use, RA symptom duration, smoking status and anti-CCP2 antibody status.

Summary statistics were generated for the mean change from re-treatment baseline to the end of re-treatment in DAS28-CRP and Health Assessment Questionnaire-Disability Index (HAQ-DI) scores, and for proportions of patients with DAS28-CRP remission and LDA at the end of re-treatment. Re-treatment baseline was the last assessment within 30 days before the first re-treatment dose. DAS28-CRP was also summarised by original treatment group, where baseline was the day of starting re-treatment. The 95% CIs for mean change was based on a t-test. Achievement of DAS28-CRP remission at the end of re-treatment was tested using an adjusted logistic regression model, including the same parameters used for the Cox proportional-hazards model.

Deaths, serious adverse events (SAEs) and serious infections were summarised over the withdrawal and re-treatment periods. Overall infection rates were compared over all study periods.

Results {#s3}
=======

Patient disposition and baseline characteristics {#s3-1}
------------------------------------------------

Of 351 randomised patients, 290 (82.6%) completed the treatment period and 225 (64.1%) entered the withdrawal period after achieving LDA, with 176/225 (78.2%) being in remission. Of the 225 patients, 172 (76.4%) discontinued the withdrawal phase due to RA flare, of whom 146/172 (84.9%) entered and 140/146 (95.9%) completed the re-treatment period. Six months after the initiation of the withdrawal period (month 18), 17/115 (14.8%), 14/113 (12.4%) and 9/115 (7.8%) patients in the abatacept plus methotrexate, abatacept and methotrexate arms, respectively, had a sustained remission.

For patients who entered the withdrawal and re-treatment periods, baseline characteristics ([table 1](#T1){ref-type="table"}) were similar to those of the original randomised population.[@R6]

###### 

Baseline\* demographics and disease characteristics for patients who entered the withdrawal and re-treatment periods

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                              Patients who entered the withdrawal period†   Patients who entered the re-treatment period‡                                                                    
  ------------------------------------------- --------------------------------------------- ----------------------------------------------- ------------ ------------ ------------ ------------ ------------ ------------
  Age, years (median)                         47.1±12.4\                                    44.5±12.2\                                      49.0±12.8\   47.0±12.5\   46.1±11.5\   44.1±12.1\   47.7±12.7\   45.9±12.0\
                                              (48.0)                                        (43.5)                                          (48.0)       (46.0)       (44.0)       (44.5)       (48.0)       (45.5)

  Weight, years (median)                      72.2±16.0\                                    69.4±14.9\                                      76.3±18.3\   72.7±16.6\   71.5±16.5\   70.9±14.7\   74.7±17.2\   72.3±16.1\
                                              (69.0)                                        (69.0)                                          (74.0)       (70.0)       (68.2)       (69.3)       (74.0)       (69.7)

  RA duration, years                          0.58±0.52                                     0.64±0.57                                       0.47±0.47    0.56±0.52    0.59±0.54    0.65±0.58    0.49±0.49    0.58±0.54

  RF positive, n (%)                          81 (96.4)                                     63 (95.5)                                       70 (95.9)    214 (96.0)   55 (100.0)   45 (93.8)    42 (97.7)    142 (97.3)

  SJC (28 joints)                             15.3±11.7                                     17.1±12.7                                       15.1±11.8    15.8±12.0    17.2±13.0    19.7±13.3    17.8±13.4    18.2±13.2

  Patient Global Assessment (0--100 mm VAS)   59.8±21.9                                     56.8±22.0                                       57.1±19.3    58.0±21.0    62.3±23.0    58.6±20.5    59.1±19.5    60.2±21.1

  DAS28-CRP                                   5.4±1.2                                       5.4±1.1                                         5.3±1.3      5.3±1.2      5.6±1.3      5.6±1.2      5.5±1.3      5.6±1.2

  HAQ-DI                                      1.4±0.7                                       1.3±0.6                                         1.3±0.6      1.3±0.7      1.5±0.7      1.4±0.7      1.5±0.6      1.4±0.7
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are mean±SD unless indicated otherwise. In the total randomised population, 31.9% (112/351) of patients were receiving oral and/or injectable corticosteroids at baseline: 31.1% (37/119) with abatacept plus MTX, 34.5% (40/116) with abatacept monotherapy and 30.2% (35/116) with MTX monotherapy.

\*Baseline is day 1 of the initial randomised treatment period.

†For the following assessments, patient numbers in the abatacept plus MTX, abatacept and MTX arms and total population, respectively, were weight, 83, 66, 73 and 222; SJC, 84, 65, 73 and 222; Patient Global Assessment, 82, 63, 72 and 217; DAS28-CRP, 81, 63, 72 and 216; HAQ-DI, 80, 63, 67 and 210.

‡For the following assessments, patient numbers in the abatacept plus MTX, abatacept and MTX arms and total population, respectively, were SJC, 55, 47, 43 and 145; Patient Global Assessment, 54, 45, 42 and 141; DAS28-CRP, 53, 45, 42 and 140; HAQ-DI, 55, 46, 40 and 141.

§Baseline characteristics for patients entering the withdrawal period were summarised using the database lock for the first analysis (7 November 2013). Two patients in the MTX group entered the withdrawal period after the first database lock and therefore were not included.

DAS28-CRP, Disease Activity Score 28-C reactive protein; HAQ-DI, Health Assessment Questionnaire--Disability Index; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; SD, standard deviation; SJC, swollen joint count; VAS, Visual Analogue Scale.

Efficacy: withdrawal period {#s3-2}
---------------------------

Proportions of patients maintaining DAS28-CRP--defined drug-free remission remained numerically higher in the original abatacept plus methotrexate and abatacept arms versus methotrexate arm to day 253 of withdrawal (month 21: 15/73 (20.5%), 11/50 (22.0%) and 11/53 (20.8%), respectively). At the end of the withdrawal period (month 24), the number of patients still in remission was very low and similar across the treatment arms: 9/73 (12.3%) with abatacept plus methotrexate, 7/50 (14.0%) with abatacept and 6/53 (11.3%) with methotrexate ([online supplementary figure S1](#SP1){ref-type="supplementary-material"}). The same results were seen when using alternative definitions of disease remission: CDAI, SDAI and Boolean remission, and LDA ([online supplementary table S1](#SP1){ref-type="supplementary-material"}).

10.1136/rmdopen-2018-000840.supp1

Patients who experienced a flare during the withdrawal period and subsequently entered the re-treatment period (n=146) were studied to determine if any characteristic at study entry could predict an earlier flare after treatment withdrawal. Kaplan-Meier curves for time to protocol-defined first flare during withdrawal showed no clear differences between randomisation arms ([figure 2](#F2){ref-type="fig"}). Cox proportional-hazards model of time to first flare after treatment withdrawal using various baseline parameters identified that only corticosteroid use at baseline was associated with a faster time to flare (p=0.0159; [table 2](#T2){ref-type="table"}).

###### 

Cox proportional-hazards model of time to RA flare after study medication withdrawal\*

  Baseline parameter                        HR (95% CI)           P value
  ----------------------------------------- --------------------- ------------
  Treatment                                                       
   Abatacept+MTX vs MTX                     0.71 (0.46 to 1.09)   0.1171
   Abatacept vs MTX                         0.80 (0.51 to 1.25)   0.3276
  DAS28-CRP                                 0.84 (0.64 to 1.11)   0.2231
  SJC (28 joints)                           1.02 (1.00 to 1.04)   0.1060
  PtGA (0--100 mm VAS)                      1.00 (0.99 to 1.01)   0.9692
  Baseline corticosteroid use (yes vs no)   1.71 (1.11 to 2.63)   **0.0159**
  RA symptom duration (\<3 vs ≥3 months)    0.97 (0.66 to 1.42)   0.8588
  Smoking status (yes† vs no)               0.91 (0.63 to 1.33)   0.6376
  Anti-CCP2 (positive vs negative)          1.06 (0.73 to 1.54)   0.7543

HRs and p values were based on a Cox proportional-hazards model including the following baseline parameters: randomised treatment, DAS28-CRP, SJC, PtGA, corticosteroid use, RA symptom duration, smoking status and anti-CCP2 antibody status. RA flare was defined as ≥2 of doubling of tender and swollen joint counts from month 12, increase in DAS28-CRP ≥1.2 from month 12 or investigator's clinical judgement of RA.

\*All randomised and treated patients who entered the withdrawal period (n=146).

†Includes previous and current smokers.

Anti-CCP2, anticyclic citrullinated peptide 2; DAS28-CRP, Disease Activity Score 28-C reactive protein; MTX, methotrexate; PtGA, Patient Global Assessment of Disease Activity; RA, rheumatoid arthritis; SJC, swollen joint count; VAS, Visual Analogue Scale.

![Cox proportional-hazards model of time to first RA flare after treatment withdrawal for patients who entered the re-treatment period (n=146). Patients who experienced a flare during the withdrawal period and subsequently entered the re-treatment period were included in this analysis. Kaplan-Meier curves for time to protocol-defined first flare during withdrawal are shown. The Cox proportional-hazards model included the following baseline parameters: randomised treatment, DAS28-CRP, swollen joint count, Patient Global Assessment of Disease Activity, corticosteroid use, RA symptom duration, smoking status and anticyclic citrullinated peptide 2 antibody status. RA flare was defined as ≥2 of doubling of tender and swollen joint counts from month 12, increase in DAS28-CRP ≥1.2 from month 12 or investigator's clinical judgement of RA. DAS28-CRP, Disease Activity Score 28-C reactive protein; MTX, methotrexate; RA, rheumatoid arthritis.](rmdopen-2018-000840f02){#F2}

Efficacy: re-treatment period {#s3-3}
-----------------------------

As noted, only patients who experienced a flare between month 3 and month 12 of the withdrawal period entered the re-treatment period; a high proportion of these patients entered the re-treatment period and had evaluable efficacy data. Overall, 120 and 106 patients had DAS28-CRP and HAQ-DI assessments, respectively, within 30 days before the first re-treatment dose and after 6 months of re-treatment.

During re-treatment, mean (SD) DAS28-CRP decreased from 5.28 (1.37) to 2.41 (0.94); mean change (95% CI) −2.87 (−3.13 to --2.60). There were no notable differences in mean improvement in DAS28-CRP by initial treatment arm ([online supplementary table S2](#SP1){ref-type="supplementary-material"}). After 6 months' re-treatment, most evaluable patients (76.6%; 95/124) had reached LDA (DAS28-CRP \<3.2), with 62.9% (78/124) achieving remission (DAS28-CRP\<2.6). Mean (SD) HAQ-DI scores decreased during re-treatment: 1.40 (0.63) versus 0.64 (0.57); mean change (95% CI) −0.76 (−0.88 to --0.64).

Using an adjusted logistic regression model with the same baseline characteristics used to identify factors that could predict faster time to flare, only PtGA at study entry was associated with subsequent achievement of DAS28-CRP remission after re-treatment (p=0.0199; [table 3](#T3){ref-type="table"}).

###### 

Predictive factors for the achievement of DAS28-CRP remission at the end of the re-treatment period\*

  Baseline parameter                        OR (95% CI)            P value
  ----------------------------------------- ---------------------- ------------
  Treatment                                                        
   Abatacept†+MTX vs MTX                    1.71 (0.63 to 4.63)    0.6923
   Abatacept vs MTX                         2.07 (0.74 to 5.77)    0.3026
  DAS28-CRP                                 0.80 (0.44 to 1.47)    0.4727
  SJC (28 joints)                           1.00 (0.96 to 1.05)    0.9271
  PtGA (0--100 mm VAS)                      0.97 (0.94 to 1.00)†   **0.0199**
  Baseline corticosteroid use (yes vs no)   1.34 (0.55 to 3.28)    0.5219
  RA symptom duration (\<3 vs ≥3 months)    1.08 (0.44 to 2.66)    0.8634
  Smoking status (yes‡ vs no)               1.16 (0.49 to 2.79)    0.7346
  Anti-CCP2 (positive vs negative)§         1.62 (0.69 to 3.80)    0.2730

ORs and p values were based on an adjusted logistic regression model including the following baseline parameters: randomised treatment, DAS28-CRP, SJC, PtGA, corticosteroid use, RA symptom duration, smoking status and anti-CCP2 antibody status.

\*All randomised and treated patients who entered the withdrawal period.

†Due to rounding, the upper 95% CI value of 0.995 is shown as 1.00.

‡Includes previous and current smokers.

§At the end of the treatment period, respectively, 8/98 (8%), 1/85 (1%) and 1/94 (1%) of patients treated with abatacept+methotrexate, abatacept and methotrexate became anti-CCP2 seronegative.

Anti-CCP2, anticyclic citrullinated peptide 2; DAS28-CRP, Disease Activity Score 28-C reactive protein; MTX, methotrexate; PtGA, Patient Global Assessment of Disease Activity; RA, rheumatoid arthritis; SJC, swollen joint count; VAS, Visual Analogue Scale.

Safety {#s3-4}
------

Two deaths were reported during the study, both in the methotrexate arm during withdrawal (due to respiratory failure and uterine neoplasm/renal failure). Neither was considered by the investigators to be related to study treatment.

During withdrawal, 7/225 patients had an SAE; two in the abatacept plus methotrexate arm (prostate cancer and postprocedural complication) and five in the methotrexate arm (foot deformity, sciatica, respiratory failure, uterine neoplasm and renal failure, and pyelonephritis and urinary tract infection (all n=1)). None were considered to be related to study treatment. During re-treatment, 4/146 patients had an SAE (tendon rupture, cholangitis, anaemia and abatacept overdose). Only abatacept overdose was considered related to the study drug.

Infection rates were low during the withdrawal and re-treatment periods, particularly when compared with the initial treatment period ([table 4](#T4){ref-type="table"}). No marked differences were seen between original treatment groups in the rate or type of infections. One serious infection was reported during treatment withdrawal (pyelonephritis in the methotrexate arm; 337.4 patient-years) and none during re-treatment (292.2 patient-years).

###### 

Exposure-adjusted incidence rates of infection per 100 patient-years during the treatment, withdrawal and re-treatment periods

  ------------------------------------------------------------------------------------------------
                  Treatment months 0--6\   Treatment months 6--12\   Withdrawal\   Re-treatment\
                  (n=351)                  (n=351)                   (n=225)       (n=146)
  --------------- ------------------------ ------------------------- ------------- ---------------
  Overall rate    --                       --                        8.9\*         16.1†

  Abatacept+MTX   116.6                    64.6                      7.2           17.2

  Abatacept       126.1                    66.5                      6.0           9.3

  MTX             110.7                    72.8                      13.5          22.3
  ------------------------------------------------------------------------------------------------

\*All patients who entered the withdrawal period.

†All patients who experienced protocol-defined rheumatoid arthritis flare after treatment withdrawal, entered the re-treatment period and received open-label abatacept+MTX.

MTX, methotrexate.

Discussion {#s4}
==========

AVERT investigated the feasibility of drug withdrawal in early RA, and employed the rapid withdrawal of all RA therapies and a strict definition of disease flare. This approach is not recommended in clinical practice. To our knowledge, this is the only controlled study in which the efficacy and safety of re-treatment have been examined. This unique analysis showed that re-treatment with abatacept plus methotrexate in patients experiencing disease flare after treatment withdrawal could restore remission or LDA in many patients.

During the 12 months following treatment withdrawal, most patients could not remain in drug-free remission, with many experiencing a flare within 6 months. Benefits of abatacept plus methotrexate versus methotrexate alone at 6 months after treatment withdrawal[@R6] did not persist over the second 6 months off treatment. Population selection criteria for severe disease used in this study---early, active disease and poor prognostic indicators (anticitrullinated peptide antibody (ACPA) positive)[@R6]---were inadequate to discern long-term drug-free remission. Only corticosteroid use at study entry was associated with shorter time to flare after treatment withdrawal, which may reflect greater disease severity in patients using corticosteroids or the difficulties associated with corticosteroid withdrawal.[@R6] Notably, in ADJUST, a phase II double-blind treatment withdrawal trial, patients with undifferentiated or very early RA and ACPA positivity were treated with intravenous abatacept or placebo for 6 months, followed by treatment discontinuation. Patients receiving abatacept showed delayed disease progression and prolonged inhibition of radiographic progression after cessation of treatment versus placebo, and a decrease from baseline in rheumatoid factor and ACPA titres (however, the titres failed to reach the limits of normal).[@R9]

Most patients experiencing a flare entered the re-treatment period, during which treatment with abatacept plus methotrexate notably reduced disease activity and improved physical function. LDA was recaptured in three quarters of patients, with two-thirds regaining remission. This is notable given the relatively high disease activity, as captured by the mean DAS28-CRP values, of study patients at the time of flare. Only PtGA predicted recapture of remission during re-treatment, suggesting that patients are the best judges of their own disease.

Very few SAEs were reported in the withdrawal or re-treatment periods. For the first time to our knowledge, lower infection rates were demonstrated in the withdrawal and re-treatment periods versus the initial treatment period. Infection rates in RA studies are usually regarded as an indicator of disease-modifying antirheumatic drug (DMARD)--associated toxicity. However, infection rates, including serious infections, probably reflect a complex interplay between the RA state, the disease-activity level and all therapies employed.[@R10] The observed infection rate in the withdrawal period ([table 3](#T3){ref-type="table"}) may simply reflect the absence of DMARD use. However, this does not explain the relatively similar rate of infection during re-treatment, notably in the group initially receiving methotrexate, without previous exposure to abatacept. A linear relationship was demonstrated between serious infection rates and disease activity, with infection rates and disease activity tending to decrease over time on treatment.[@R12] Further understanding of the factors influencing the development of infections and their interactions will assist in designing better, less toxic treatment strategies. The relative safety of withdrawal and re-treatment in this setting can, however, be stressed.

Limitations of this analysis include the high discontinuation rate before the second 6 months of the withdrawal period. At study conception, a formal definition of flare was unavailable; therefore, the designers formulated their own robust definition. However, the Outcome Measures in Rheumatology Clinical Trials RA Flare Core Domain Set is now available[@R13] and may have use in future clinical trials and practice by testing domains using the RA-flare questionnaire.[@R14]

This analysis demonstrates that, after receiving only 12 months of DMARD therapy before withdrawal of all RA treatments, few patients with severe early RA can maintain drug-free remission over 12 months. However, for those experiencing disease flare after treatment withdrawal, this unique investigation showed that re-treatment with abatacept plus methotrexate can restore remission or LDA in many patients, with good tolerability.
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